TGA Therapeutic Goods Administration
PO Box 100, Woden, ACT 2606, Australia
☑ Woden Telephone: (06) 289 1555. Fax: (06) 289 8709
☐ Mawson Telephone: (06) 286 0222. Fax: (06) 286 1386

COMMONWEALTH DEPARTMENT OF HEALTH, HOUSING AND COMMUNITY SERVICES

DE B1 FILE 93/16630
DE FILE 93/11783
CONTROL NO. 91.156.2

The Managing Director
Marion Merrell Dow Australia Pty Ltd
Locked Mail Bag 30
Frenchs Forest NSW 2080

ATTENTION: REGULATORY AFFAIRS OFFICER

f84 86/09010

Dear Sir

I refer to your application dated 29 July 1991, for registration of Targocid in the Australian Register of Therapeutic Goods (ARTG) under the provisions of the Therapeutic Goods Act 1989 ("the Act").

f40 93/16630 f75 93/11783 f225 91/10911

Evaluation of your application (Control No. 91.156.2) has been completed.

Approval is now granted under Section 25(3) of the Act for the registration of:
i) Targocid 100mg, containing 100mg teicoplanin per vial, as a composite pack also containing one 1.7mL diluent ampoule of Water for Injections B.P.,
ii) Targocid 200mg, containing 200mg teicoplanin per vial, as a composite pack also containing one 3.14mL diluent ampoule of Water for Injections B.P.,
iii) Targocid 400mg, containing 400mg teicoplanin per vial, as a composite pack also containing one 3.14mL diluent ampoule of Water for Injections B.P.,
for the indications stated herein.

Supply is not permitted until each therapeutic good is registered.

Registration will not be effected until your company has agreed in writing to the description of the goods as detailed in this letter. Registration will commence on the day specified in the Certificate of Registration. You should complete all necessary steps to effect registration within three months of the date of this letter. Please confirm in writing that the product details contained in this letter are accurate in accordance with your application and any amendment properly notified during the course of the evaluation.

All separate and distinct goods within the meaning of Section 16(1) of the Act that have been approved following this evaluation are included in this registration approval.

For the purposes of Section 28 of the Act, (Conditions on registration or listing) registration of each good described in this approval is subject to the following specific conditions.

DESCRIPTION OF GOODS FOR ACCEPTABILITY TO SUPPLY.

NAME:

Targocid (teicoplanin).

MANUFACTURER INFORMATION.

MANUFACTURER:

Gruppo Lepetit S.p.A
Località Valcanello
Anagni (Frosinone) Italy

STEPS:

Manufacture of dose form, packaging, labelling and quality control testing for teicoplanin and Water for Injections.

MANUFACTURER:

Gruppo Lepetit S.p.A.
Zona ex Punto Franco
72100 Brindisi Italy

STEP:

Manufacture of active ingredient (teicoplanin).

MANUFACTURER:

Sigma Pharmaceuticals Pty. Ltd.
Croydon, Victoria, Australia

STEP:

Visual examination of finished product for teicoplanin and Water for Injections.

PRODUCT DETAILS.

PRODUCT PROPRIETARY NAME:
Targocid

PRODUCT GENERIC NAME:
Teicoplanin

PACK SIZE: **POISON SCHEDULE:**S4.
1 x 5mL vial plus 1 x ampoule of Water for Injections B.P.

f96 93/16630 + f95 93/16630

DOSAGE FORM:
Injection, powder for (lyophilised)

ADMINISTRATION ROUTES:
Intravenous
Intramuscular

CONTAINER TYPE:
Vial - 5mL colourless U.S.P. Type 1 glass with butyl rubber plug and aluminium ring seal.

VISUAL IDENTIFICATION:
Ivory coloured lyophilised powder.

STERILE: YES.
STERILISATION TYPE:
Dry heat - vials
Steam (Autoclave) - rubber closures - f101 93/16630
Irradiation (gamma rays) - seals.

ANIMAL ORIGIN: YES.
Type of microbe: Actinoplanes teichomyceticus.

FORMULATION:

Active ingredients:	nominal content per vial
Teicoplanin	100 mg (125 mg)*
Excipients:	
Sodium chloride	11.440mg (14.3mg)*

f94 93/16630

* The above nominal contents have in addition a 25% approved overage in each vial.

SHELF LIFE:
The potency of this product lies between 95-130% of the labelled content of teicoplanin 100mg during its approved shelf life.

Time:	3 years
Temperature:	Below 25°C f94 93/16630
Other Conditions:	None

PRODUCT DETAILS.

PRODUCT PROPRIETARY NAME:
Targocid

PRODUCT GENERIC NAME:
Teicoplanin

PACK SIZE: **POISON SCHEDULE:** S4.
1 x 10mL vial plus 1 x ampoule of Water for Injections B.P.

DOSAGE FORM:
Injection, powder for (lyophilised)

ADMINISTRATION ROUTES:
Intravenous
Intramuscular

CONTAINER TYPE:
Vial - 10mL colourless U.S.P. Type 1 glass with butyl rubber plug and aluminium ring seal.

VISUAL IDENTIFICATION:
Ivory coloured lyophilised powder.

STERILE: YES.
STERILISATION TYPE:
Dry heat - vials
Steam (Autoclave) - rubber closures
Irradiation (gamma rays) - seals.

ANIMAL ORIGIN: YES.
Type of microbe: Actinoplanes teichomyceticus.

	FORMULATION:	
Active ingredients:	nominal content per vial	
Teicoplanin	200 mg	(220 mg)*
Excipients:		
Sodium chloride	21.818mg	(24.0mg)*

* The above nominal contents have in addition a 10% approved overage in each vial.

SHELF LIFE:
The potency of this product lies between 95-115% of the labelled content of teicoplanin 200mg during its approved shelf life.

Time:	3 years
Temperature:	Below 25°C
Other conditions:	None

PRODUCT DETAILS.

PRODUCT PROPRIETARY NAME:
Targocid

PRODUCT GENERIC NAME:
Teicoplanin

f96
93/16630

PACK SIZE: **POISON SCHEDULE:**S4.
1 x 25mL vial plus 1 x ampoule of Water for Injections B.P.

DOSAGE FORM:
Injection, powder for (lyophilised)

ADMINISTRATION ROUTES:
Intravenous
Intramuscular

CONTAINER TYPE:
Vial - 25mL colourless U.S.P. Type 1 glass with butyl rubber plug and aluminium ring seal.

f95
93/16630

VISUAL IDENTIFICATION:
Ivory coloured lyophilised powder.

STERILE: YES.
STERILISATION TYPE:
Dry heat - vials
Steam (Autoclave) - rubber closures - f101 93/16630
Irradiation (gamma rays) - seals.

ANIMAL ORIGIN: YES.
Type of microbe: Actinoplanes teichomyceticus.

	FORMULATION: nominal content per vial	
Active ingredients:		
Teicoplanin	400 mg	(460 mg)*
Excipients:		
Sodium chloride	21.565mg	(24.8 mg)*

f94
93/16630

* The above nominal contents have in addition a 15% approved overage in each vial.

SHELF LIFE:
The potency of this product lies between 95-120% of the labelled content of teicoplanin 400mg during its approved shelf life.

Time:	3 years
Temperature:	Below 25°c f94 93/16630
Other conditions:	None

PRODUCT DETAILS.

PRODUCT PROPRIETARY NAME:
Water for Injections B.P.

PRODUCT GENERIC NAME:
Water for Injections.

PACK SIZE:
1 x Ampoule.

POISON SCHEDULE: None.

DOSAGE FORM:
Injection.

ADMINISTRATION ROUTES:
Intravenous
Intramuscular

CONTAINER TYPE:
Ampoule - colourless U.S.P. Type 1 glass.

VISUAL IDENTIFICATION:
Clear colourless liquid.

STERILE: YES.
STERILISATION TYPE:
Steam (Autoclave)

ANIMAL ORIGIN: NO.

FORMULATION:

Active ingredients:	per ampoule
Water for Injections	1.7 mL
(present as 11.8% overage =	1.9 mL)

SHELF LIFE:

Time:	3 years
Temperature:	Below 25°C
Other Conditions:	None

PRODUCT DETAILS.

PRODUCT PROPRIETARY NAME:
Water for Injections B.P.

PRODUCT GENERIC NAME:
Water for Injections.

93 93/16630

PACK SIZE:
1 x Ampoule.

POISON SCHEDULE: None.

DOSAGE FORM:
Injection.

ADMINISTRATION ROUTES:
Intravenous
Intramuscular

CONTAINER TYPE:
Ampoule - colourless U.S.P. Type 1 glass.

VISUAL IDENTIFICATION:
Clear colourless liquid.

STERILE: YES.
STERILISATION TYPE:
Steam (Autoclave). – fig 93/16630

fal 93/16630

ANIMAL ORIGIN: NO.

FORMULATION:

Active ingredients:	per ampoule
Water for Injections	3.14mL
(present as 1.91% overage =	3.2 mL)

SHELF LIFE:

Time:	3 years
Temperature:	Below 25°C
Other Conditions:	None

4D

INDICATIONS:

Targocid is indicated for the treatment of the following infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including β-lactam antibiotics:-

Bone - osteomyelitis
Joints - septic arthritis
Blood - non-cardiac bacteraemia, septicaemia.

PRODUCT INFORMATION:

The product information submitted with your letter of 21 January 1994, as amended 3 February 1994, is considered satisfactory.

PATIENT INFORMATION:

In accordance with Regulation 9(A) a consumer product information document is required to be available for supply to the patient or agent. The format of this document is set out in Schedule 12 of the Regulations. The patient information document submitted with your letter of 2 February 1994 is considered to meet the format as presented in Schedule 12 of the Regulations and not to contain any statement contrary to the approved product information.

CONDITIONS

SPECIAL CONDITIONS APPLYING TO THIS PRODUCT.

(1) The Therapeutic Goods Administration Laboratories Branch (TGAL) is to be notified immediately the first production batches of these products are available for official sampling, under the terms of Regulation 24 of the Therapeutic Goods Act 1989. This information should be sent to the Director, Therapeutic Goods Administration Laboratories Branch, PO Box 100, Woden, ACT 2606.

(2) Appropriate quantities of the reference material for the active ingredient, as well as of precursors, degradation products and other impurities for which limits are set in the finished product specifications are to be provided free of charge to the TGA, if required by TGAL.

(3) Proposed changes to the approved chemical, pharmaceutical and biological details and specifications should be forwarded for evaluation by the Drug Evaluation Branch (DEB) and must be approved prior to implementation, apart from a self-assessable change or a change which can be notified to the DEB or the Australian Register of Therapeutic Goods (ARTG) as detailed in Appendices 7 & 8 to the document entitled "Australian Guidelines for Registration of Drugs, Vol. 1 - Prescription and Other Specified Drug Products" (AGRD1). [Appendices 7 and 8 are entitled, respectively , "Changes to drug products - Is notification or prior approval required" and "Changes which may be made to pharmaceutical aspects of drug products without prior approval (self-assessable changes)"]. Changes to test methods and specifications may also be required following laboratory analysis of the product by TGAL.

Please note: approved chemical, pharmaceutical and biological details and specifications include all those details on which approval is based in relation to sponsor, finished product details, formulation, active raw materials, excipients, manufacturing process, quality control, and packaging. (Refer to the AGRD Appendices 7 and 8 specified above).

(4) The Product Information (reference 4.21 AGRD1) must meet with the TGA's approval at all times. With the exception of safety related changes that further

restrict the use of the product, which must be notified to the TGA within five working days, any proposed changes to the approved text must be submitted and be accepted by the Administration prior to any distribution.

The safety related changes referred to above are defined as those that delete an indication or reduce the patient population, or add a warning, precaution, adverse reaction or contraindication.

The Product Information should conclude with a statement that it has been approved by the Therapeutic Goods Administration (TGA), citing the date of the approval letter. **One copy of the final printed version of the Product Information is to be forwarded to the Drug Evaluation Branch.** For all parenteral products the Product Information must be included with the product as a package insert.

Abridged Product Information must accurately reflect the approved Product Information, including safety related statements, but may be a paraphrase or precis of the approved product information.

(5) Product literature, excluding Product Information, relating to the registered good does not require the Administration's approval provided it is based on and includes:

(I) in the first two years of marketing, the full text of the latest approved product information, or

(II) thereafter, abridged product information;

and does not represent the goods in a manner by which they could be taken to be separate and distinct goods in terms of Section 16 of the Act (i.e. to be used for a purpose or represented in a manner other than that for which they are registered).

(6) The actual date of commencement of supply is to be notified to the Director, Drug Evaluation Branch, in addition to notifying the ARTG. Should it be decided not to proceed to supply, notification to this effect should be provided.

(7) A report is to be provided annually for three years from the date of commencement of supply which shall include details of:

(a) all investigational studies relating to the chemical and physical properties, including stability of the drug under storage;

(b) all pharmacological and toxicological studies conducted or reported, including studies recorded in scientific literature;

(c) all clinical studies conducted or reported in Australia or abroad, including studies recorded in scientific literature, and a bibliography of these reports;

(d) all suspected adverse reactions or related experiences received, including full clinical details.

The above information, in duplicate, should be forwarded to the TGA at the appropriate time.

Details of the distribution of the drug including quantities and forms of products distributed and related batch numbers should be supplied on request while the drug remains on the ARTG.

(8) It is a condition of registration that as the sponsor of this product you will comply with Section 24 of the Therapeutic Goods Regulations 1990.

(9) It is a condition of registration that your company must inform the TGA if an application is rejected in the USA or Canada at any time during or after registration in Australia and must submit detailed reasons for the rejection.

Conditions applicable to all registered goods are at Attachment 2.

You should be aware that..

Pursuant to the Customs (Prohibited Imports) Regulations a current permit to import is required for antibiotics and may be obtained from;

The Head
Antibiotics Section
Therapeutic Goods Administration Laboratories.

This decision is an "initial decision" within the meaning of Section 60 of the Therapeutic Goods Act 1989 ("the Act"). This means that if you are a person whose interests are affected by this decision, and you wish to appeal against this decision, you may do so in writing to the Minister under Section 60 of the Act. Any appeal should be made in writing within 90 days after this decision first comes to your notice or the notice of your company, and should be sent to the following address:

Minister for Family Services,
Parliament House,
CANBERRA ACT 2600

The letter should be headed 'APPEAL UNDER SECTION 60 OF THE THERAPEUTIC GOODS ACT, 1989'.

In accordance with the Act the Minister may delegate the power to consider an appeal. Should you be dissatisfied with the result of your appeal then, subject to the Administrative Appeals Tribunal Act 1975, you may apply to the Administrative Appeals Tribunal for a review of the Minister's/Delegate's decision. This course of action should only be embarked upon when discussions between yourself and officers of the Drug Evaluation Branch have failed.

Yours faithfully

[redacted]

[redacted]

DELEGATE OF THE SECRETARY
7 FEBRUARY 1994

Attachments:
1. Approved Product Information.
2. Standard Conditions Applying to Registered or Listed Therapeutic Goods under Section 28 of the Therapeutic Goods Act 1989.
3. Registration Form.

THE SECRETARY
POISONS SCHEDULE STANDING COMMITTEE

THE SECRETARY
ADVERSE DRUG REACTIONS SUBCOMMITTEE

ASSISTANT SECRETARY
PHARMACEUTICAL BENEFITS BRANCH

THE EDITOR
AUSTRALIAN PRESCRIBER

THE SECRETARY
AUSTRALIAN DRUG EVALUATION COMMITTEE

APPROVAL FOR REGISTRATION AS A THERAPEUTIC GOOD IN AUSTRALIA.

You are advised that approval has been granted on 7 February 1994 under the provisions of the Therapeutic Goods Act 1989 to:
Marion Merrell Dow Australia Pty Ltd
Locked Mail Bag 30
Frenchs Forest NSW 2080
for the registration of:

i) Targocid 100mg, containing 100mg teicoplanin per vial, as a composite pack also containing one 1.7mL diluent ampoule of Water for Injections B.P.,
ii) Targocid 200mg, containing 200mg teicoplanin per vial, as a composite pack also containing one 3.14mL diluent ampoule of Water for Injections B.P.,
iii) Targocid 400mg, containing 400mg teicoplanin per vial, as a composite pack also containing one 3.14mL diluent ampoule of Water for Injections B.P.,

Targocid is indicated for the treatment of the following infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including β-lactam antibiotics:-

- Bone - osteomyelitis
- Joints - septic arthritis
- Blood - non-cardiac bacteraemia, septicaemia.

A copy of the approved Product Information is attached.

Director
Drug Evaluation Branch
7 FEBRUARY 1994

PRODUCT INFORMATION

TARGOCID®
(TEICOPLANIN FOR INJECTION)

Description:

Teicoplanin is a glycopeptide-antibiotic produced by *Actinoplanes teichomyceticus*. It is presented as a sterile, pyrogen-free ivory white powder for reconstitution with water for injection. It is freely soluble in water and on reconstitution gives a clear solution.

Microbiology:

Teicoplanin is bactericidal or bacteriostatic on growing populations of susceptible Gram-positive organisms; depending on the sensitivity of the organism and antibiotic concentration.

Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a different site from that affected by β-lactams. Teicoplanin is therefore effective against staphylococci (including those resistant to methicillin and other β-lactam antibiotics) and streptococci.

Some cross-resistance is observed between teicoplanin and the glycopeptide vancomycin.

Teicoplanin has shown no cross-resistance to β-lactam antibiotics, macrolides, aminoglycosides, tetracycline, rifampicin or chloramphenicol.

Human Pharmacokinetics:

In man, the plasma level profile after intravenous administration indicates a biphasic distribution (with a rapid distribution phase having a half-life of about 0.3 hours, followed by a more prolonged distribution phase having a half-life of 3 hours). At the end of the distribution phase plasma levels, and the subsequent time-concentration curves, are identical following intramuscular or intravenous administration of 3 mg/kg dose. Following intramuscular injection bioavailability is 100 %; average peak plasma levels of 7.1µg/mL are achieved in 3-4 hours following a dose of 3 mg/kg.

The elimination half-life is 70-100 hours. The apparent volume of distribution at steady state is similar to total body water, i.e. 0.6 L/kg.

Approximately 90-95 % of teicoplanin is bound to plasma proteins. Teicoplanin penetrates into blister exudates and bone where it achieves peak concentrations comparable to those in serum after intramuscular injection. Peak levels in joint fluid are approximately 60 % of peak serum concentrations. Teicoplanin penetrates very poorly into cerebrospinal fluid (CSF) and red blood cells.

Metabolic transformation is minor, about 3 %; about 80 % of administered drug is excreted in the urine over a 16 day collection period.

Indications:

Targocid® is indicated for the treatment of the following serious infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including β-lactam antibiotics :-

Bone	- osteomyelitis
Joints	- septic arthritis
Blood	- non-cardiac bacteraemia, septicaemia

Contraindications:

Targocid® is contraindicated in patients with a known hypersensitivity to the drug.

Warnings and Precautions:

Targocid® should be administered with caution in patients known to be hypersensitive to vancomycin since cross-hypersensitivity may occur. However, a history of the "Red Man Syndrome" that can occur with vancomycin is not a contraindication to Targocid®.

Periodic haematological studies, and renal and liver function tests are advised during prolonged treatment.

Serial renal and auditory function tests should be undertaken in the following circumstances:

- In patients receiving prolonged therapy.
- In patients with renal insufficiency.
- During concurrent and sequential use of other drugs which may have ototoxic or nephrotoxic properties. These include aminoglycosides, amphotericin, cyclosporin, cysplatin, frusemide and ethacrynic acid. However, there are no toxicity data on the concurrent use of these drugs with Targocid®.

The use of Targocid® may result in overgrowth of non-susceptible organisms. If new infections due to bacteria or fungi appear during treatment, appropriate measures should be taken.

The safety and efficacy of Targocid® by the intrathecal route has not been studied.

Interactions:

No conclusive data are available from controlled clinical studies on interactions with other drugs.

Use in Pregnancy and Lactation: (Use in pregnancy category B3)

Reproductive studies in rats and rabbits with subcutaneous doses up to 200 mg/kg/day and 15 mg/kg/day respectively did not reveal teratogenic effects. Teicoplanin was associated with an increase in the number of stillborn pups when rats were treated with subcutaneous doses ≥ 100 mg/kg/day. Pup weight was reduced at all doses tested (SC doses ≥ 10 mg/kg/day). It is not known if teicoplanin is excreted in breast milk during lactation.

Targocid® should not be used during confirmed or presumed pregnancy or during lactation unless the potential benefits outweigh possible risks.

Carcinogenesis and Mutagenesis

Long-term studies in animals to evaluate the carcinogenic potential of teicoplanin have not been performed. Teicoplanin was negative in assays evaluating the potential to cause gene mutations, but assays to evaluate the potential to cause chromosome damage have not been performed.

Adverse Reactions:

In an open clinical trial involving patients with bone or joint infections, teicoplanin was associated with adverse reactions in 32 % of the patients. However, treatment was discontinued because of adverse reactions in 17 % of patients only. A clear cause-effect relationship was not established in these patients. The most frequent adverse reactions were fever, rashes, nausea, vomiting, rigors, pruritus and diarrhoea.

The following adverse effects have been reported.

- Local reactions: pain, phlebitis, redness, abscess
- Hypersensitivity: skin rash, erythema or pruritus, rigor, fever, bronchospasm or anaphylaxis
- Hepatic: increased transaminases and/or alkaline phosphatase
- Haematologic: eosinophilia, thrombocytopenia, leucopenia
- Renal: rise in serum creatinine, blood urea, acute renal failure
- Gastrointestinal: nausea or vomiting, diarrhoea
- Nervous system: dizziness, headache
- Auditory: hearing loss, tinnitus,vertigo

Dosage and administration:

Note: Special instruction apply for reconstitution. See below.

The reconstituted Targocid® injection should be administered intravenously or intramuscularly. Intravenous dosing may be by slow injection over 5 minutes or by infusion over 30 minutes. Maintenance dosage is once daily; however, initially a loading dose regimen of three doses at 12-hourly intervals is recommended, for rapid attainment of steady-state plasma levels.

An intramuscular injection of Targocid® should not exceed 3 mL (400 mg) at a single site.

Adults:

Septicaemia/bacteraemia, acute or chronic osteomyelitis:
Treatment should be started with 400-800 mg (or 6-12 mg/kg) by the I.V. route every 12 hours for 3 doses then the daily maintenance dose should be 400 mg (or 6 mg/kg).

Septic arthritis
Patients with septic arthritis should receive 800 mg (or 12 mg/kg), intravenously, every 12 hours for 3 doses then a daily maintenance dose of 800 mg (or 12 mg/kg).

Elderly Patients:

As for adults. If renal function is impaired, the instructions for impaired renal function should be followed.

While the total duration of therapy is determined by the type and severity of infection and by the clinical response of the patient, the following periods are often appropriate:

- Uncomplicated bacteraemia 2-4 weeks
- Septic arthritis or osteomyelitis 3-6 weeks

Patients with Renal Impairment:

For patients with impaired renal function, reduction of dosage is not required until the fourth day of Targocid® treatment. Trough plasma teicoplanin concentrations should be monitored periodically after the first week of therapy and the dosage adjusted to prevent trough concentrations exceeding 30 µg/mL in patients with septic arthritis or 15 µg/mL in other cases.

From the fourth day of treatment

- **in mild renal insufficiency:**
  creatinine clearance between 40 and 60 mL/min, Targocid® dose should be halved, either by administering the initial unit dose every two days, or by administering half of this dose once a day.
- **in severe renal insufficiency:**
  creatinine clearance less than 40 mL/min, and in haemodialysed patients, Targocid® dose should be one third of the normal either by administering the initial unit dose every third day, or by administering one third of this dose once a day. **Teicoplanin is not removed by dialysis.**

Preparation of Injection:

Note: The powder should be reconstituted strictly in accordance with the instructions below. Errors in reconstitution may result in the formation of a stable foam and delivery of smaller doses.

The entire contents of the accompanying diluent water ampoule should be added slowly down the side wall of the vial of Targocid®. The vial should be rolled gently between the palms until the powder is completely dissolved, taking care to avoid foam formation. DO NOT SHAKE. If the solution does become foamy, allow to stand for 15 minutes for the foam to subside. Withdraw the entire contents from the vial slowly into a syringe, trying to recover most of the solution by placing the needle in the central part of the stopper.

Satisfactory potency of the reconstituted injection is retained for 48 hours at 25 °C and for 7 days at 4 °C. As a matter of good pharmaceutical practice, it is recommended that reconstituted solutions be stored under refrigeration (4 °C) and solutions stored longer than 24 hours be discarded.

The reconstituted solution contains:

For the 100 mg vial: 100 mg/1.5 mL of teicoplanin.
For the 200 mg vial: 200 mg/3.0 mL of teicoplanin.
For the 400 mg vial: 400 mg/3.0 mL of teicoplanin.

The reconstituted solution may be injected directly, or alternatively diluted with any of the following diluents.

- 0.9 % Sodium Chloride solution
- Compound sodium lactate solution

If necessary, solutions with the above diluents may be stored at 4 °C for up to 7 days. Solutions left at room temperature for longer than 24 hours should be discarded.

- 5 % glucose solution
- 0.18 % Sodium Chloride and 4 % glucose solution

Solutions containing the above diluents (which contain glucose) should be stored at 4 °C and should be used within 24 hours; solutions kept longer than 24 hours should be discarded.

As a matter of good pharmaceutical practice, solutions for intravenous infusion should be used immediately after admixing.

OVERDOSAGE

Treatment of overdosage should be symptomatic. Teicoplanin is not removed by haemodialysis or peritoneal dialysis.

PRESENTATION

- Targocid® 100 mg- 5 mL vial containing lyophilised 125 mg* teicoplanin and 14.3 mg sodium chloride with an accompanying ampoule (1.7 mL*) Water for Injections (Ph. Eur.)

- Targocid® 200 mg- 10 mL vial containing lyophilised 220 mg* teicoplanin and 24 mg sodium chloride with an accompanying ampoule (3.14 mL*) Water for Injections (Ph. Eur.)

- Targocid® 400 mg- 25 mL vial containing lyophilised 460 mg* teicoplanin and 24.8 mg sodium chloride with an accompanying ampoule (3.14 mL*) Water for Injections (Ph. Eur.)

* An overage is included to allow withdrawal of the correct dose.

Manufactured/Supplied by :
Marion Merrell Dow Australia Pty. Ltd.
Unit 1, 25 Frenchs Forest Rd. East
Frenchs Forest
NSW 2086

01/94

METHOD OF PREPARATION

1.

Each vial contains TEICOPLANIN.

2.



Each AMPOULE contains sterile Water for Injections.

WITHDRAW ALL the water from the ampoule with a syringe.

SLOWLY inject all the water into the vial; about 0.2 ml of water will remain in the syringe.



GENTLY roll the vial between the hands until the powder is completely dissolved, paying attention to avoid the formation of foam.

IT IS IMPORTANT TO ENSURE THAT ALL THE POWDER IS DISSOLVED, EVEN THAT NEAR THE STOPPER.

6.



Withdraw the teicoplanin solution slowly from the vial, trying to recover most of it by placing the needle in the central part of the rubber stopper.

7.



The concentration of a carefully prepared solution will be 100 mg in 1.5 ml (from the 200 mg vial) and 400 mg in 3 ml (from the 400 mg vial). Shaking this solution will cause the formation of foam which will make it difficult to recover the expected volume. Nevertheless, if teicoplanin has been completely dissolved the foam does not change the concentration of the solution which will remain 100 mg in 1.5 ml (from the 200 mg vial) or 400 mg in 3 ml (from the 400 mg vial). If the solution does become foamy then it should be left to stand for about 15 minutes. It is important that the solution is correctly prepared and carefully withdrawn since the syringe preparations that are not carefully executed can lead to the administration of less than 50% of the dose.